Hypoglycemia in type 2 diabetes: A critical review

Glen H. Murata, William C. Duckworth, Richard M. Hoffman, Christopher S. Wendel, M. Jane Mohler, Jayendra H. Shah

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Hypoglycemia is the most important barrier to tight glycemic control. Although severe hypoglycemia is uncommon, milder events can occur so often that they represent a deterrent to intensifying treatment. High-risk patient behaviors are the most important cause for episodes for which a cause can be identified. Because symptoms are an unreliable way of establishing the diagnosis, SMBG should be considered for the patients at highest risk, particularly as they approach their glycemic targets. SMBG is superior to HbA1c in forecasting the hypoglycemia rate because it provides information about glucose variability--an independent risk factor. Patient education and medication changes are potential ways of reducing the hypoglycemia rate. However, it remains to be proven that patient education is beneficial in this regard.

Original languageEnglish (US)
Pages (from-to)551-559
Number of pages9
JournalBiomedicine and Pharmacotherapy
Issue number10
StatePublished - Dec 2004


  • Diabetes mellitus, type II
  • Hypoglycemia
  • Hypoglycemic agents
  • Insulin
  • Risk factors

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Hypoglycemia in type 2 diabetes: A critical review'. Together they form a unique fingerprint.

Cite this